热门资讯> 正文
眼部疾病药物第二阶段失败后，KALA比奥股价暴跌92%
2025-09-29 20:56
- Shares of KALA Bio (BIO) have plummeted ~92% in premarket trading Monday after reporting that a phase 2 trial of its persistent corneal epithelial defect (PCED) candidate KPI-012 missed its key goal.
- Besides missing the primary endpoint of complete healing of PCED as measured by corneal fluorescein staining, the CHASE trial also missed on secondary efficacy endpoints.
- As a result, KALA will end development of KPI-012 -- which was its lead product -- along with its mesenchymal stem cell secretome (MSC-S) platform.
- Also, the company will evaluate strategic options and preserve cash, including cutting staff.
More on KALA BIO
- Seeking Alpha’s Quant Rating on KALA BIO
- Historical earnings data for KALA BIO
- Financial information for KALA BIO
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
